Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 11Urinary Bladder Neoplasms 6Carcinoma, Renal Cell 4Ovarian Neoplasms 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Pancreatic Neoplasms 2Melanoma 2Lung Neoplasms 2Colonic Neoplasms 2Urologic Neoplasms 1Urologic Diseases 1Ureteral Neoplasms 1Stroke 1Stomach Neoplasms 1Sarcoma 1Renal Insufficiency, Chronic 1Recurrence 1Rectal Neoplasms 1Pulmonary Disease, Chronic Obstructive 1Neoplasms 1Myelodysplastic Syndromes 1Localized Prostate Carcinoma 1Leukemia, Myeloid, Acute 1Kidney Failure, Chronic 1Hypogonadism 1Esophageal Neoplasms 1Disease Progression 1Diabetes Mellitus 1Coronary Artery Disease 1

Interventions

Nutrition Assessment 2tocilizumab 1Standard of Care 1Resistance Training 1Practice Guidelines as Topic 1Massage 1Lysine Acetyltransferase 5 1Immunoglobulin G 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stroke × Practice Guidelines as Topic × Genitourinary × Clear all
NCT04361552 2020-06-18

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Emory University

Phase 3 Withdrawn
Genitourinary

COVID-19, Coronary Artery Disease, Diabetes Mellitus, Kidney Failure, Chronic, Neoplasms, Stroke, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡